4.7 Article

NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation

期刊

BLOOD
卷 115, 期 13, 页码 2686-2694

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-07-229740

关键词

-

资金

  1. Swedish Foundation for Strategic Research
  2. Swedish Research Council
  3. Swedish Cancer Society
  4. Swedish Children's Cancer Foundation
  5. Cancer Society of Stockholm
  6. Royal Swedish Academy of Sciences
  7. Tobias Foundation
  8. Soderberg Foundation
  9. Belven Foundation
  10. Ake Wiberg Foundation
  11. Stockholm County Council
  12. Karolinska Institutet

向作者/读者索取更多资源

Natural killer (NK)-cell alloreactivity in recipients of hematopoietic stem cell grafts from HLA-identical siblings is intriguing and has suggested breaking of NK-cell tolerance during the posttransplantation period. To examine this possibility, we analyzed clinical outcomes in a cohort of 105 patients with myeloid malignancies who received T cell-replete grafts from HLA-matched sibling donors. Presence of inhibitory killer cell immunoglobulin-like receptors (KIRs) for nonself HLA class I ligands had no effect on disease-free survival, incidence of relapse, or graft-versus-host disease. A longitudinal analysis of the NK-cell repertoire and function revealed a global hyporesponsiveness of NK cells early after transplantation. Functional responses recovered at approximately 6 months after transplantation. Importantly, NKG2A(-) NK cells expressing KIRs for nonself HLA class I ligands remained tolerant at all time points. Furthermore, a direct comparison of NK-cell reconstitution in T cell-replete and T cell-depleted HLA-matched sibling stem cell transplantation (SCT) revealed that NKG2A(+) NK cells dominated the functional repertoire early after transplantation, with intact tolerance of NKG2A(-) NK cells expressing KIRs for nonself ligands in both settings. Our results provide evidence against the emergence of alloreactive NK cells in HLA-identical allogeneic SCT. (Blood. 2010;115(13):2686-2694)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Dentistry, Oral Surgery & Medicine

Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis

Karin Garming Legert, Olle Ringden, Mats Remberger, Johan Torlen, Jonas Mattsson, Goran Dahllof

Summary: The study found that using tacrolimus plus sirolimus as a prophylaxis for graft-versus-host disease following haematopoietic stem cell transplantation did not increase the incidence or severity of oral mucositis, nor did it prolong the healing time compared to cyclosporine plus methotrexate.

ORAL DISEASES (2021)

Article Hematology

Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care

Olle Ringden, Mats Remberger, Johan Torlen, Sigrun Finnbogadottir, Britt-Marie Svahn, Behnam Sadeghi

Summary: Patients treated at home post-HCT showed decreased cytokine levels, improved survival, and lower rates of III-IV acute GVHD compared to patients treated in the hospital. Various factors such as GVHD grade, donor type, conditioning regimen, and graft source influenced cytokine levels and outcomes.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)

Article Biophysics

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

Mary-Elizabeth Percival, Hai-Lin Wang, Mei-Jie Zhang, Wael Saber, Marcos de Lima, Mark Litzow, Partow Kebriaei, Hisham Abdel-Azim, Kehinde Adekola, Mahmoud Aljurf, Ulrike Bacher, Sherif M. Badawy, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Bhatt, Michael Byrne, Jean-Yves Cahn, Paul Castillo, Nelson Chao, Saurabh Chhabra, Edward Copelan, Corey Cutler, Zachariah DeFilipp, Ajoy Dias, Miguel Angel Diaz, Elihu Estey, Nosha Farhadfar, Haydar A. Frangoul, Cesar O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael Grunwald, Nasheed Hossain, Rammurti T. Kamble, Christopher G. Kanakry, Ankit Kansagra, Mohamed A. Kharfan-Dabaja, Maxwell Krem, Hillard M. Lazarus, Jong Wook Lee, Jane L. Liesveld, Richard Lin, Hongtao Liu, Joseph McGuirk, Reinhold Munker, Hemant S. Murthy, Sunita Nathan, Taiga Nishihori, Richard F. Olsson, Neil Palmisiano, Jakob R. Passweg, Tim Prestidge, Olov Ringden, David A. Rizzieri, Witold B. Rybka, Mary Lynn Savoie, Kirk R. Schultz, Sachiko Seo, Akshay Sharma, Melhem Solh, Roger Strair, Marjolein van der Poel, Leo F. Verdonck, Jean A. Yared, Daniel Weisdorf, Brenda M. Sandmaier

Summary: The study found that in AML patients, those in CRi had increased risk of death compared to those in CR, along with higher non-relapse mortality, shorter disease-free survival, and increased relapse. Detectable MRD was associated with shorter overall survival, shorter disease-free survival, higher non-relapse mortality, and increased relapse. The detrimental effects of CRi and MRD were independent.

BONE MARROW TRANSPLANTATION (2021)

Article Oncology

Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation

Neema P. Mayor, Tao Wang, Stephanie J. Lee, Michelle Kuxhausen, Cynthia Vierra-Green, Dominic J. Barker, Jeffrey Auletta, Vijaya R. Bhatt, Shahinaz M. Gadalla, Loren Gragert, Yoshihiro Inamoto, Gerald P. Morris, Sophie Paczesny, Ran Reshef, Olle Ringden, Bronwen E. Shaw, Peter Shaw, Stephen R. Spellman, Steven G. E. Marsh

Summary: This study found that UHR HLA matching may not increase overall survival probability, but it does reduce the risk of aGVHD and in certain subsets, transplant-related mortality. Matching at the UHR level warrants consideration when choosing between multiple 10 out of 10 HLA-matched donors.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Multidisciplinary Sciences

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome

Anne-Sophie Chretien, Raynier Devillier, Samuel Granjeaud, Charlotte Cordier, Clemence Demerle, Nassim Salem, Julia Wlosik, Florence Orlanducci, Laurent Gorvel, Stephane Fattori, Marie-Anne Hospital, Jihane Pakradouni, Emilie Gregori, Magali Paul, Philippe Rochigneux, Thomas Pagliardini, Mathieu Morey, Cyril Fauriat, Nicolas Dulphy, Antoine Toubert, Herve Luche, Marie Malissen, Didier Blaise, Jacques A. Nunes, Norbert Vey, Daniel Olive

Summary: The accumulation of CD56(-)CD16(+) unconventional NK cells in patients with acute myeloid leukemia may be a consequence of immune escape from innate immunity during AML progression.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Oncology

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Raynier Devillier, Boris Calmels, Sophie Guia, Mohammed Taha, Cyril Fauriat, Bechara Mfarrej, Geoffroy Venton, Eric Vivier, Daniel Olive, Christian Chabannon, Didier Blaise, Sophie Ugolini

Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective curative option for high-risk hematologic malignancies, but disease recurrence remains a critical issue. NK cell-based immunotherapies offer a promising approach to enhance anti-tumor effects without triggering graft-versus-host disease. This clinical trial demonstrates the safety and potential efficacy of prophylactic donor-derived IL-2 activated NK cell infusion after allo-HSCT for patients with hematologic malignancies.

CANCERS (2021)

Article Hematology

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Matthew J. Wieduwilt, Leland Metheny, Mei-Jie Zhang, Hai-Lin Wang, Noel Estrada-Merly, David Marks, A. Samer Al-Homsi, Lori Muffly, Nelson Chao, David Rizzieri, Robert Peter Gale, Shahinaz M. Gadalla, Mitchell Cairo, Alberto Mussetti, Steven Gore, Vijaya Raj Bhatt, Sagar S. Patel, Fotios Michelis, Yoshihiro Inamoto, Sherif M. Badawy, Edward Copelan, Neil Palmisiano, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Siddhartha Ganguly, Christopher Bredeson, Miguel Angel Diaz Perez, Ryan Cassaday, Bipin N. Savani, Karen Ballen, Rodrigo Martino, Baldeep Wirk, Ulrike Bacher, Mahmoud Aljurf, Asad Bashey, Hemant S. Murthy, Jean A. Yared, Ibrahim Aldoss, Nosha Farhadfar, Hongtao Liu, Hisham Abdel-Azim, Edmund K. Waller, Melhem Solh, Matthew D. Seftel, Marjolein van der Poel, Michael R. Grunwald, Jane L. Liesveld, Rammurti T. Kamble, Joseph McGuirk, Reinhold Munker, Jean-Yves Cahn, Jong Wook Lee, Cesar O. Freytes, Maxwell M. Krem, Lena E. Winestone, Usama Gergis, Sunita Nathan, Richard F. Olsson, Leo F. Verdonck, Akshay Sharma, Olle Ringden, Brian D. Friend, Jan Cerny, Hannah Choe, Saurabh Chhabra, Taiga Nishihori, Sachiko Seo, Biju George, Lee Ann Baxter-Lowe, Gerhard C. Hildebrandt, Marcos de Lima, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Muhammad Bilal Abid, Daniel J. Weisdorf, Wael Saber

Summary: This study compared the outcomes of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) with other HCT approaches for acute lymphoblastic leukemia (ALL) patients. The results showed that haploidentical HCT using PTCy had similar overall survival (OS) but lower incidence of chronic graft-versus-host disease (cGVHD) compared to traditional matched sibling and unrelated donor HCT methods, making it a preferred alternative donor option for ALL patients in complete remission.

BLOOD ADVANCES (2022)

Article Immunology

Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia

Berna Bou-Tayeh, Vladimir Laletin, Nassim Salem, Sylvaine Just-Landi, Joanna Fares, Raphael Leblanc, Marielle Balzano, Yann M. Kerdiles, Ghislain Bidaut, Olivier Herault, Daniel Olive, Michel Aurrand-Lions, Thierry Walzer, Jacques A. Nunes, Cyril Fauriat

Summary: NK cells in AML patients exhibit defects in maturation and function due to chronic cytokine activation, particularly IL-15/mTOR signaling, leading to metabolic and functional exhaustion.

FRONTIERS IN IMMUNOLOGY (2021)

Review Immunology

Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome

Olle Ringden, Guido Moll, Britt Gustafsson, Behnam Sadeghi

Summary: This article summarizes the authors' more than 20 years of scientific experience in the clinical use of MSCs and DSCs in different clinical settings. MSCs and DSCs have significant effects on the immune system and coagulation, and show potential clinical efficacy in conditions such as acute GvHD, ARDS, and hemorrhages.

FRONTIERS IN IMMUNOLOGY (2022)

Article Cell & Tissue Engineering

Immunomodulation by placenta-derived decidua stromal cells. Role of histocompatibility, accessory cells and freeze-thawing

Behnam Sadeghi, Myrese Witkamp, Dominik Schefberger, Anna Arbman, Olle Ringden

Summary: Human placenta-derived decidua stromal cells (DSCs) have been used in clinical trials for the treatment of acute inflammatory diseases, but the mechanisms of action and interaction with other immune cells require further exploration.

CYTOTHERAPY (2023)

Article Immunology

Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review

Behnam Sadeghi, Olle Ringden, Britt Gustafsson, Markus Castegren

Summary: Acute respiratory distress syndrome (ARDS) is a life-threatening lung disease. Mesenchymal stromal cells (MSCs) have been evaluated as a therapy for ARDS, and the use of MSCs for ARDS induced by Covid-19 has shown positive results. Clinical and experimental studies have demonstrated the effectiveness of MSCs in treating sepsis and ARDS.

FRONTIERS IN IMMUNOLOGY (2022)

Article Medicine, Research & Experimental

Downregulation of stromal syntenin sustains AML development

Raphael Leblanc, Rania Ghossoub, Armelle Goubard, Remy Castellano, Joanna Fares, Luc Camoin, Stephane Audebert, Marielle Balzano, Berna Bou-Tayeh, Cyril Fauriat, Norbert Vey, Sylvain Garciaz, Jean-Paul Borg, Yves Collette, Michel Aurrand-Lions, Guido David, Pascale Zimmermann

Summary: This study reveals a vicious signaling loop potentially at the heart of AML-stroma crosstalk and unexpected tumor-suppressive effects of syntenin that need to be considered during systemic targeting of syntenin in cancer therapy.

EMBO MOLECULAR MEDICINE (2023)

Article Hematology

Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation

Alvaro Haroun-Izquierdo, Pilar M. Lanuza, Aline Pfefferle, Herman Netskar, Eivind H. Ask, Johan Torlen, Andreas Bjorklund, Ebba Sohlberg, Karl -Johan Malmberg

Summary: Sirolimus, an inhibitor of mTOR, shows potential as a component of GVHD prophylaxis regimens in HSCT, but detailed immunologic studies are lacking. This study evaluated the effect of sirolimus on immune reconstitution using longitudinal patient samples. Sirolimus inhibited naive cell suppression and NK cell reconstitution, leading to impaired proliferation and functional responses.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis

Rima M. Salibaaw, Amin M. Alousia, Joseph Pidala, Mukta Arora, Stephen R. Spellman, Michael T. Hemmer, Tao Wang, Camille Abboudg, Sairah Ahmed, Joseph H. Antin, Amer Beitinjanehi, David K. Buchbinder, Michael Byrne, Jean-Yves Cahn, Hannah Choen, Rabi Hanna, Peiman HemattiP, Rammurti T. Kamble, Carrie L. Kitkor, Mary Laughlin, Lazaros Lekakis, Margaret L. MacMillan, Rodrigo Martino, Parinda A. Mehta, Taiga Nishihori, Sagar S. Patel, Miguel-Angel Perales, Hemalatha G. Rangarajan, Olov Ringden, Joseph Rosenthal, Bipin N. Savani, Kirk R. Schultz, Sachiko Seo, Takanori Teshimaag, Marjolein van der Poela, Leo F. Verdonck, Daniel Weisdorf, Baldeep Wirk, Jean A. Yared, Jeffrey Schriber, Richard E. Champlin, Stefan O. Ciurea

Summary: This retrospective registry study compared the distribution, severity, and outcomes of graft-versus-host disease (GvHD) in patients receiving haploidentical (Haplo) transplantation with post-transplantation cyclophosphamide (PTCy) prophylaxis and HLA-matched unrelated donor transplantation with conventional prophylaxis. The study found that Haplo/PTCy transplantation was associated with reduced rates of severe acute GvHD and chronic GvHD, particularly in the gastrointestinal (GI) tract.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Article Hematology

Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

Leland Metheny, Natalie S. Callander, Aric C. Hall, Mei-Jei Zhang, Khalid Bo-Subait, Hai-Lin Wang, Vaibhav Agrawal, A. Samer Al-Homsi, Amer Assal, Ulrike Bacher, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Chris Bredeson, Michael Byrne, Mitchell Cairo, Jan Cerny, Zachariah DeFilipp, Miguel Angel Diaz Perez, Esar O. Freytes, Siddhartha Ganguly, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Yoshihiro Inamoto, Christopher G. Kanakry, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Jong Wook Lee, Sunita Nathan, Taiga Nishihori, Richard F. Olsson, Olov Ringden, David Rizzieri, Bipin N. Savani, Mary Lynn Savoie, Sachiko Seo, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Jean A. Yared, Christopher S. Hourigan, Partow Kebriaei, Mark Litzow, Brenda M. Sandmaier, Wael Saber, Daniel Weisdorf, Marcos de Lima

Summary: The prognosis for patients with therapy-related myeloid neoplasm, including myelodysplastic syndrome (t-MDS) and acute myelogenous leukemia (t-AML), is poor. Although modern supportive care and conditioning regimens have improved outcomes, the major cause of treatment failure remains relapse. Caution is advised when recommending allogeneic hematopoietic cell transplantation, and more effective antineoplastic approaches are needed.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

暂无数据